Financials data is unavailable for this security.
View more
Year on year Krka dd Novo Mesto had net income fall -13.58% from 363.30m to 313.95m despite a 5.18% increase in revenues from 1.72bn to 1.81bn.
| Gross margin | 56.10% |
|---|---|
| Net profit margin | 19.52% |
| Operating margin | 21.43% |
| Return on assets | 12.64% |
|---|---|
| Return on equity | 15.80% |
| Return on investment | 14.86% |
More ▼
Cash flow in EURView more
In 2023, cash reserves at Krka dd Novo Mesto fell by 344.92m. However, the company earned 227.25m from its operations for a Cash Flow Margin of 12.58%. In addition the company used 343.24m on investing activities and also paid 229.82m in financing cash flows.
| Cash flow per share | 15.01 |
|---|---|
| Price/Cash flow per share | 9.62 |
| Book value per share | 77.51 |
|---|---|
| Tangible book value per share | 74.23 |
More ▼
Balance sheet in EURView more
| Current ratio | 4.39 |
|---|---|
| Quick ratio | 3.04 |
| Total debt/total equity | 0.005 |
|---|---|
| Total debt/total capital | 0.005 |
More ▼
Growth rates in EUR
Year on year, growth in dividends per share increased 13.64% while earnings per share excluding extraordinary items fell by -13.26%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
| Div yield(5 year avg) | 5.98% |
|---|---|
| Div growth rate (5 year) | 18.57% |
| Payout ratio (TTM) | 63.29% |
| EPS growth(5 years) | 13.20 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 23.46 |
More ▼
